S. Baumhueter et al., GLOBAL VASCULAR EXPRESSION OF MURINE CD34, A SIALOMUCIN-LIKE ENDOTHELIAL LIGAND FOR L-SELECTIN, Blood, 84(8), 1994, pp. 2554-2565
Extravasation of leukocytes into organized lymphoid tissues and into s
ites of inflammation is critical to immune surveillance. Leukocyte mig
ration to peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN) a
nd Peyer's patches (PP) depends on L-selectin, which recognizes carboh
ydrate-bearing, sialomucin-like endothelial cell surface glycoproteins
. Two of these ligands have been identified at the molecular level. On
e is the potentially soluble mucin, GlyCAM 1, which is almost exclusiv
ely produced by high endothelial venules (HEV) of PLN and MLN. The sec
ond HEV ligand for L-selectin is the membrane-bound sialomucin CD34. H
istorically, this molecule has been successfully used to purify human
pluripotent bone marrow stem cells, and limited data suggest that huma
n CD34 is present on the vascular endothelium of several organs. Here
we describe a comprehensive analysis of the vascular expression of CD3
4 in murine tissues using a highly specific antimurine CD34 polyclonal
antibody. CD34 was detected on vessels in all organs examined and was
expressed during pancreatic and skin inflammatory episodes. A subset
of HEV-like vessels in the inflamed pancreas of nonobese diabetic (NOD
) mice are positive for both CD34 and GlyCAM 1, and bind to an L-selec
tin/immunoglobulin G (IgG) chimeric probe. Finally, we found that CD34
is present on vessels of deafferentiated PLN, despite the fact that t
hese vessels are no longer able to interact with L-selectin or support
lymphocyte binding in vitro or trafficking in vivo. Our data suggest
that the regulation of posttranslational carbohydrate modifications of
CD34 is critical in determining its capability to act as an L-selecti
n ligand. Based on its ubiquitous expression, we propose that an appro
priately glycosylated form of vascular CD34 may act as a ligand for L-
selectin-mediated leukocyte trafficking to both lymphoid and nonlympho
id sites. (C) 1994 by The American Society of Hematology.